Vera Therapeutics (NASDAQ:VERA) Insider Laurence Matthew Skelton Sells 1,582 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider Laurence Matthew Skelton sold 1,582 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $66,412.36. Following the completion of the transaction, the insider owned 64,218 shares in the company, valued at approximately $2,695,871.64. This trade represents a 2.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Vera Therapeutics Trading Down 0.1%

Vera Therapeutics stock traded down $0.03 during midday trading on Thursday, reaching $41.66. The stock had a trading volume of 413,146 shares, compared to its average volume of 1,007,519. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The stock has a market capitalization of $2.92 billion, a PE ratio of -10.43 and a beta of 1.16. The stock’s 50-day simple moving average is $46.63 and its 200 day simple moving average is $35.30. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $56.05.

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VERA. GAMMA Investing LLC boosted its holdings in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the period. Optimize Financial Inc increased its stake in Vera Therapeutics by 1.5% in the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares during the last quarter. Virtus Investment Advisers LLC boosted its stake in shares of Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after buying an additional 290 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of Vera Therapeutics by 2.4% in the 4th quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after acquiring an additional 424 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after acquiring an additional 550 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Late-stage clinical and regulatory wins: Vera reported positive Phase 3 ORIGIN 3 data for atacicept in IgA nephropathy, the results were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA granted priority review to the atacicept BLA and set a PDUFA date of July 7, 2026; the company expects a potential U.S. commercial launch in mid‑2026. Management also says recent 2025 equity and debt financings leave the company well-funded into and beyond launch — a major de‑risking for revenue expectations. Read More.
• Neutral Sentiment: Quarterly results: VERA posted an adjusted EPS loss of ($1.28) that beat consensus (‑$1.34) by $0.06, which reduces near‑term execution uncertainty but still reflects a wider year‑over‑year loss (prior period: ‑$0.72). The beat is modest and does not change the company’s path to commercialization-driven valuation. Read More.
• Negative Sentiment: Significant insider selling: Several senior executives sold shares on Feb 23 (CEO Marshall Fordyce sold 16,925 shares at ~$41.98, reducing his stake by ~6.2%; CFO, COO and other officers also sold). Concentrated insider sales can signal personal liquidity taking and may create short‑term selling pressure or investor caution despite the positive program news. Read More.

Wall Street Analysts Forecast Growth

VERA has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, January 21st. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research note on Friday, December 5th. The Goldman Sachs Group boosted their price target on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.